Akari Therapeutics
Market Cap
US$39.4m
Last Updated
2019/09/20 01:08 UTC
Data Sources
Company Financials +
Executive Summary
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.
Snowflake
Fundamentals
Moderate growth potential with worrying balance sheet.
Risks
- Akari Therapeutics has significant price volatility in the past 3 months.
- Akari Therapeutics is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Akari Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.0%
AKTX
0.2%
US Pharmaceuticals
-0.2%
US Market
1 Year Return
-8.5%
AKTX
-9.3%
US Pharmaceuticals
1.1%
US Market
AKTX matched the Pharmaceuticals industry (-8.9%) over the past year.
AKTX underperformed the Market in United States of America which returned 1.6% over the past year.
Share holder returns
| AKTX | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | 0.2% | -0.2% |
| 30 Day | 3.2% | 0.3% | 2.5% |
| 90 Day | -9.8% | -5.4% | 1.6% |
| 1 Year | -8.5%-8.5% | -7.1%-9.3% | 3.4%1.1% |
| 3 Year | -78.5%-78.5% | 11.4%3.7% | 45.2%35.8% |
| 5 Year | n/a | 21.6%8.7% | 62.6%44.8% |
Price Volatility Vs. Market
How volatile is Akari Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What Type Of Shareholder Owns Akari Therapeutics, Plc's (NASDAQ:AKTX)?3 months ago | Simply Wall St
What You Must Know About Akari Therapeutics, Plc's (NASDAQ:AKTX) Beta Value6 months ago | Simply Wall St
Imagine Owning Akari Therapeutics (NASDAQ:AKTX) And Trying To Stomach The 84% Share Price DropValuation
Is Akari Therapeutics undervalued based on future cash flows and its price relative to the stock market?
In this section, we usually try to help investors determine whether Akari Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Akari Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at Akari Therapeutics's' forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Akari Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
66.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Unable to determine if Akari Therapeutics is high growth as no revenue estimate data is available.
Akari Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Unable to compare Akari Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Akari Therapeutics's earnings growth is expected to exceed the United States of America market average.
Akari Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Akari Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Akari Therapeutics performed over the past 5 years?
0.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Akari Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
Unable to compare Akari Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Akari Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Akari Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
Return on Assets
It is difficult to establish if Akari Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Akari Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Next Steps
Financial Health
How is Akari Therapeutics's financial position?
Financial Position Analysis
Akari Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Akari Therapeutics has no long term commitments.
Debt to Equity History and Analysis
Akari Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
Irrelevant to check if Akari Therapeutics's debt level has increased considering it has negative shareholder equity.
Balance Sheet
Low level of unsold assets.
Akari Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Akari Therapeutics has less than a year of cash runway based on current free cash flow.
Akari Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.8% each year.
Next Steps
Dividend
What is Akari Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Akari Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Akari Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Akari Therapeutics has not reported any payouts.
Unable to verify if Akari Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Akari Therapeutics has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Akari Therapeutics's salary, the management and board of directors tenure and is there insider trading?
3.7yrs
Average board tenure
CEO
Clive Richardson (54yo)
1.3yrs
Tenure
US$773,966
Compensation
Mr. Clive Richardson serves as the Chief Executive Officer of Akari Therapeutics, Plc since 2019. Mr. Richardson has been the Chief Operations Officer and Director of Akari Therapeutics, Plc since Septembe ...
CEO Compensation Analysis
Clive's remuneration is higher than average for companies of similar size in United States of America.
Clive's compensation has increased whilst company is loss making.
Board Age and Tenure
3.7yrs
Average Tenure
69yo
Average Age
The tenure for the Akari Therapeutics board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Ray Prudo (74yo)
Executive Chairman
- Tenure: 4yrs
- Compensation: US$318.27k
Clive Richardson (54yo)
COO, CEO & Director
- Tenure: 1.3yrs
- Compensation: US$773.97k
Miles Nunn
Chief Scientific Officer
- Tenure: 0yrs
Board Members
Don Williams (60yo)
Director
- Tenure: 3.3yrs
- Compensation: US$78.65k
Ray Prudo (74yo)
Executive Chairman
- Tenure: 4yrs
- Compensation: US$318.27k
Clive Richardson (54yo)
COO, CEO & Director
- Tenure: 1.3yrs
- Compensation: US$773.97k
James Hill (73yo)
Director
- Tenure: 4yrs
- Compensation: US$75.66k
Stuart Ungar (75yo)
Director
- Tenure: 4yrs
- Compensation: US$65.36k
David Byrne (59yo)
Director
- Tenure: 3.4yrs
- Compensation: US$65.36k
Michael Grissinger (65yo)
Director
- Tenure: 1.7yrs
- Compensation: US$85.19k
Peter Feldschreiber (75yo)
Director
- Tenure: 1.7yrs
- Compensation: US$85.19k
Company Information
Akari Therapeutics, Plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Akari Therapeutics, Plc
- Ticker: AKTX
- Exchange: NasdaqCM
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$39.389m
- Shares outstanding: 20.41m
- Website: https://www.akaritx.com
Number of Employees
Location
- Akari Therapeutics, Plc
- 75/76 Wimpole Street
- London
- W1G 9RT
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AKTX | NasdaqCM (Nasdaq Capital Market) | Yes | SPON ADR EACH REPR 100 ORD | US | USD | Jun 2014 |
| CLAB | DB (Deutsche Boerse AG) | Yes | SPON ADR EACH REPR 100 ORD | DE | EUR | Jun 2014 |
Biography
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/20 01:08 |
| End of Day Share Price | 2019/09/19 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.